
RANI Stock Forecast & Price Target
RANI Analyst Ratings
Bulls say
Rani Therapeutics Hldgs is a clinical-stage biotherapeutics company developing a proprietary RaniPill delivery platform that can enable the oral administration of traditionally injectable biologics. This platform has been validated in multiple Phase 1 studies, demonstrating high bioavailability, and the potential for once-weekly oral dosing. The company has also secured partnerships with major biopharmaceutical companies and is advancing its pipeline of oral therapeutics. With an expected positive readout in the Phase 1b human PD study for RT-114, the company is well-positioned to validate its platform and attract potential partners, making it an attractive investment opportunity.
Bears say
Rani Therapeutics Hldgs is a clinical-stage biotherapeutics company with a unique platform technology, RaniPill, that offers a convenient alternative to painful injections for biologics. However, the company's extensive preclinical and in-human dataset may not be enough to assure efficacy and safety, as transit variability and chronic, repeat-dose performance remain relatively unvalidated. Additionally, the company's valuation is driven by its key franchises, which have varying probabilities of success, and any management turnover could negatively impact the company's progress and performance.
This aggregate rating is based on analysts' research of Rani Therapeutics Holdings and is not a guaranteed prediction by Public.com or investment advice.
RANI Analyst Forecast & Price Prediction
Start investing in RANI
Order type
Buy in
Order amount
Est. shares
0 shares